Proactive Investors - Run By Investors For Investors

Amryt Pharma’s Lojuxta ‘bad’ cholesterol treatment to be made available in France in early 2019

The approval from French regulators means Lojuxta will soon be available in all five of the EU’s largest markets
Lojuxta is a treatment for Homozygous Familial Hypercholesterolaemia which causes high levels of ‘bad’ cholesterol
Lojuxta is a treatment for Homozygous Familial Hypercholesterolaemia which causes high levels of ‘bad’ cholesterol

Amryt Pharma PLC’s (LON:AMYT) flagship Lojuxta drug will soon be available in all five of the EU’s largest markets after French officials agreed to reimburse patients receiving the ‘bad’ cholesterol treatment.

The drug is expected to be made available to French patients suffering from the rare condition – known in the medical sphere as Homozygous Familial Hypercholesterolaemia (HoFH) – from early next year.

READ: Lojuxta to be made available on the NHS

The approval means that Lojuxta is available across all five of the EU's major markets – France, the UK, Italy, Germany and Spain.

“A clear aim in continuing the positive momentum in Lojuxta revenues is to ensure reimbursement in our core territories,” said chief executive Joe Wiley.

“Following closely on from our recent approval with the NHS in England, where we have already started treating patients, we are now very  pleased to be able to make Lojuxta available to adult HoFH patients in France.”

HoFH is a rare life-threatening disorder that causes abnormally high levels of low-density lipoprotein (LDL) cholesterol.

Clinical trials showed Lojuxta can reduce the production and uptake of this ‘bad’ cholesterol, helping sufferers to get their cholesterol levels down to acceptable levels.

View full AMYT profile View Profile

Amryt Pharma PLC Timeline

Related Articles

skin
April 17 2019
Driving growth was Lojuxta, used to treat a rare and life-threatening disorder that causes abnormally high levels of bad cholesterol. Its sales grew to €13.6mln, up 14.2% year-on-year
patch
Sun
The New Jersey company's lead product is Twirla, a low-dose prescription contraceptive applied once weekly for three weeks, followed by a week without the patch
Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use